CNF combination as adjuvant treatment in breast cancer patients is well tolerated

Anticancer Drugs. 1997 Apr;8(4):376-8. doi: 10.1097/00001813-199704000-00010.

Abstract

In this study 194 women with breast cancer received adjuvant CNF combination therapy (cyclophosphamide, mitoxantrone and 5-fluorouracil). The side effects and acute toxicity of the regimen were recorded. Although myelosuppression is the dose-limiting factor of the CNF regimen, it was well tolerated and side effects were limited. This regimen induced no cardiotoxicity or irreversible alopecia. It is concluded that CNF is suitable as adjuvant chemotherapy for breast cancer patients.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alkaline Phosphatase / blood
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Chemotherapy, Adjuvant
  • Creatinine / blood
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Humans
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Mitoxantrone / adverse effects

Substances

  • Cyclophosphamide
  • Creatinine
  • Mitoxantrone
  • Alkaline Phosphatase
  • Fluorouracil

Supplementary concepts

  • FMC protocol